Literature DB >> 10411922

Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses.

C A Chambers1, M S Kuhns, J P Allison.   

Abstract

CTLA-4-deficient mice develop a fatal lymphoproliferative disorder, characterized by polyclonal expansion of peripheral lymphocytes. To examine the effect of restricting the CD4(+) TCR repertoire on the phenotype of CTLA-4-deficient mice and to assess the influence of CTLA-4 on peptide-specific CD4(+) T cell responses in vitro, an MHC class II-restricted T cell receptor (AND TCR) transgene was introduced into the CTLA-4(-/-) animals. The expression of the AND TCR transgene by CD4(+) T cells delays but does not prevent the lymphoproliferation in the CTLA-4(-/-) mice. The CD4(+) T cells become preferentially activated and expand. Interestingly, young AND TCR(+) CTLA-4(-/-) mice carrying a null mutation in the rag-1 gene remain healthy and the T cells maintain a naive phenotype until later in life. We demonstrate that CTLA-4 regulates the peptide-specific proliferative response generated by naive and previously activated AND TCR(+) RAG(-/-) T cells in vitro. The absence of CTLA-4 also augments the responder frequency of cytokine-secreting AND TCR(+) RAG(-/-) T cells. These results demonstrate that CTLA-4 is a key regulator of peptide-specific CD4(+) T cell responses and support the model that CTLA-4 plays a differential role in maintaining T cell homeostasis of CD4(+) vs. CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411922      PMCID: PMC17563          DOI: 10.1073/pnas.96.15.8603

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  MHC class II molecules are not required for survival of newly generated CD4+ T cells, but affect their long-term life span.

Authors:  S Takeda; H R Rodewald; H Arakawa; H Bluethmann; T Shimizu
Journal:  Immunity       Date:  1996-09       Impact factor: 31.745

Review 2.  CD28/B7 system of T cell costimulation.

Authors:  D J Lenschow; T L Walunas; J A Bluestone
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 3.  The role of CTLA-4 in the regulation and initiation of T-cell responses.

Authors:  C A Chambers; M F Krummel; B Boitel; A Hurwitz; T J Sullivan; S Fournier; D Cassell; M Brunner; J P Allison
Journal:  Immunol Rev       Date:  1996-10       Impact factor: 12.988

4.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.

Authors:  V L Perez; L Van Parijs; A Biuckians; X X Zheng; T B Strom; A K Abbas
Journal:  Immunity       Date:  1997-04       Impact factor: 31.745

5.  Ia-transfected L-cell fibroblasts present a lysozyme peptide but not the native protein to lysozyme-specific T cells.

Authors:  N Shastri; B Malissen; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

6.  Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness.

Authors:  K Matsui; J J Boniface; P Steffner; P A Reay; M M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

7.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

8.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

9.  Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4.

Authors:  L E Marengère; P Waterhouse; G S Duncan; H W Mittrücker; G S Feng; T W Mak
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

10.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

View more
  33 in total

Review 1.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

Review 2.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok; James P Allison
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

3.  Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation.

Authors:  Xuguang Tai; Francois Van Laethem; Arlene H Sharpe; Alfred Singer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

Review 4.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

5.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

Authors:  F Stephen Hodi; Martin C Mihm; Robert J Soiffer; Frank G Haluska; Marcus Butler; Michael V Seiden; Thomas Davis; Rochele Henry-Spires; Suzanne MacRae; Ann Willman; Robert Padera; Michael T Jaklitsch; Sridhar Shankar; Teresa C Chen; Alan Korman; James P Allison; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

6.  CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

Authors:  Sergio A Quezada; Karl S Peggs; Michael A Curran; James P Allison
Journal:  J Clin Invest       Date:  2006-06-15       Impact factor: 14.808

7.  CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.

Authors:  Luca Gattinoni; Anju Ranganathan; Deborah R Surman; Douglas C Palmer; Paul A Antony; Marc R Theoret; David M Heimann; Steven A Rosenberg; Nicholas P Restifo
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

8.  Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells.

Authors:  M S Kuhns; V Epshteyn; R A Sobel; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

9.  Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.

Authors:  Karl S Peggs; Sergio A Quezada; Cynthia A Chambers; Alan J Korman; James P Allison
Journal:  J Exp Med       Date:  2009-07-06       Impact factor: 14.307

10.  Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial).

Authors:  P Emery; P Durez; M Dougados; C W Legerton; J-C Becker; G Vratsanos; H K Genant; C Peterfy; P Mitra; S Overfield; K Qi; R Westhovens
Journal:  Ann Rheum Dis       Date:  2009-11-23       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.